These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37993487)

  • 21. Closed, one-stop intelligent and accurate particle characterization based on micro-Raman spectroscopy and digital microfluidics.
    Sheng H; Chen L; Zhao Y; Long X; Chen Q; Wu C; Li B; Fei Y; Mi L; Ma J
    Talanta; 2024 Jan; 266(Pt 1):124895. PubMed ID: 37454511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flow imaging: moving toward best practices for subvisible particle quantitation in protein products.
    Wilson GA; Manning MC
    J Pharm Sci; 2013 Mar; 102(3):1133-4. PubMed ID: 23303598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Convolutional Neural Networks Enable Highly Accurate and Automated Subvisible Particulate Classification of Biopharmaceuticals.
    Wang S; Liaw A; Chen YM; Su Y; Skomski D
    Pharm Res; 2023 Jun; 40(6):1447-1457. PubMed ID: 36471026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Particles in Parenteral Drug Raw Materials.
    Lee K; Lankers M; Valet O
    PDA J Pharm Sci Technol; 2018; 72(6):599-607. PubMed ID: 29669816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy.
    Narhi LO; Corvari V; Ripple DC; Afonina N; Cecchini I; Defelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Spitznagel TM; Weiskopf A; Wuchner K
    J Pharm Sci; 2015 Jun; 104(6):1899-1908. PubMed ID: 25832583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Subvisible Particles in Biopharmaceutical Formulations Using Raman Spectroscopy Provides Insight into Polysorbate 20 Degradation Pathway.
    Saggu M; Liu J; Patel A
    Pharm Res; 2015 Sep; 32(9):2877-88. PubMed ID: 25773722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A critical review of analytical methods for subvisible and visible particles.
    Narhi LO; Jiang Y; Cao S; Benedek K; Shnek D
    Curr Pharm Biotechnol; 2009 Jun; 10(4):373-81. PubMed ID: 19519412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Closing the Gap: Counting and Sizing of Particles Across Submicron Range by Flow Cytometry in Therapeutic Protein Products.
    Zhang L; Shi S; Antochshuk V
    J Pharm Sci; 2017 Nov; 106(11):3215-3221. PubMed ID: 28625725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging.
    Sharma DK; Oma P; Pollo MJ; Sukumar M
    J Pharm Sci; 2010 Jun; 99(6):2628-42. PubMed ID: 20049937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of active pharmaceutical ingredient particle size in tablets by Raman chemical imaging validated using polystyrene microsphere size standards.
    Kuriyama A; Ozaki Y
    AAPS PharmSciTech; 2014 Apr; 15(2):375-87. PubMed ID: 24414886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Micro-flow imaging multi-instrument evaluation for sub-visible particle detection.
    Fawaz I; Schaz S; Boehrer A; Garidel P; Blech M
    Eur J Pharm Biopharm; 2023 Apr; 185():55-70. PubMed ID: 36708971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Confocal Raman microscopy for investigating synthesis and characterization of individual optically trapped vinyl-polymerized surfactant particles.
    Schaefer JJ; Crawford AC; Porter MD; Harris JM
    Appl Spectrosc; 2014; 68(6):633-41. PubMed ID: 25014718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Micro-Flow Imaging: Estimation of the Contribution of Key Factors to the Variability of Subvisible Particle Count Measurement by a Nested Statistical Analysis.
    Zhang K; Wrzosek T; Desai KG; Monck M
    PDA J Pharm Sci Technol; 2020; 74(1):15-26. PubMed ID: 31519785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging Flow Cytometry for Sizing and Counting of Subvisible Particles in Biotherapeutics.
    Helbig C; Menzen T; Wuchner K; Hawe A
    J Pharm Sci; 2022 Sep; 111(9):2458-2470. PubMed ID: 35777484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanistic Investigation on Grinding-Induced Subvisible Particle Formation during Mixing and Filling of Monoclonal Antibody Formulations.
    Gikanga B; Hui A; Maa YF
    PDA J Pharm Sci Technol; 2018; 72(2):117-133. PubMed ID: 29030532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variance Between Different Light Obscuration and Flow Imaging Microscopy Instruments and the Impact of Instrument Calibration.
    Matter A; Koulov A; Singh S; Mahler HC; Reinisch H; Langer C; Zucol B; Mathaes R
    J Pharm Sci; 2019 Jul; 108(7):2397-2405. PubMed ID: 30844365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimization of Infrared Microscopy to Assess Secondary Structure of Insulin Molecules Within Individual Subvisible Particles in Aqueous Formulations.
    Schack MM; Møller EH; Friderichsen AV; Carpenter JF; Rades T; Groenning M
    J Pharm Sci; 2019 Mar; 108(3):1117-1129. PubMed ID: 30773199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subvisible Particle Analysis of 17 Monoclonal Antibodies Approved in China Using Flow Imaging and Light Obscuration.
    Guo S; Yu C; Guo X; Jia Z; Yu X; Yang Y; Guo L; Wang L
    J Pharm Sci; 2022 Apr; 111(4):1164-1171. PubMed ID: 34551350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics.
    Singh SK; Afonina N; Awwad M; Bechtold-Peters K; Blue JT; Chou D; Cromwell M; Krause HJ; Mahler HC; Meyer BK; Narhi L; Nesta DP; Spitznagel T
    J Pharm Sci; 2010 Aug; 99(8):3302-21. PubMed ID: 20310025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.